NCT01039948 - A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

203

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions

Carcinoma, Non-Small Cell-LungLung NeoplasmsLung CancerRespiratory Tract Neoplasms

Interventions

BIOLOGICAL

AV-299 + gefitinib

AV-299 is a humanized anti-HGF IgG1 monoclonal antibody directed against free HGF, ligand for c-Met tyrosine kinase receptor.

DRUG

Gefitinib

Gefitinib is a small molecule (drug) which selectively inhibits epidermal growth factor receptor's (EGFR) tyrosine kinase domain.

Trial Locations (26)

Investigational Site 1, Shatin N.T.

Investigational Site 10, Kuala Lumpur

Investigational Site 9, Kuala Lumpur

Investigational Site 11, Kuala Pahang

Investigational Site 12, Manila

Investigational Site 13, Pasig

Investigational Site 14, Quezon City

Investigational Site 15, Singapore

Investigational Site 2, Chungcheongbuk-do

Investigational Site 3, Gyeonggi-do

Investigational Site 4, Jeollanam-do

Investigational Site 5, Seoul

Investigational Site 6, Seoul

Investigational Site 7, Seoul

Investigational Site 8, Seoul

Investigational Site 16, Changhua

Investigational Site 17, Chiayi City

Investigational Site 18, Taichung

Investigational Site 19, Tainan City

Investigational Site 20, Taipei

Investigational Site 21, Taipei

Investigational Site 22, Taoyuan District

Investigational Site 23, Bangkok

Investigational Site 24, Chiang Mai

Investigational Site 25, KhonKaen

Investigational Site 26, Songkhla